

Rhodes CJ, Ghataorhe P, Wharton J, Rue-Albrecht KC, Hadinnapola C, Watson G, Bleda M, Haimel M, Coghlan G, Corris PA, Howard LS, Kiely DG, Peacock AJ, Pepke-Zaba J, Toshner MR, Wort SJ, Gibbs JSR, Lawrie A, Graf S, Morrell NW, Wilkins MR.

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.

Circulation 2017, 135(5), 460-475.

Copyright:

© 2016 The Authors. *Circulation* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

DOI link to article:

<https://doi.org/10.1161/CIRCULATIONAHA.116.024602>

Date deposited:

13/04/2017



This work is licensed under a [Creative Commons Attribution 4.0 International License](#)

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension

BACKGROUND: Pulmonary arterial hypertension (PAH) is a heterogeneous disorder with high mortality.

METHODS: We conducted a comprehensive study of plasma metabolites using ultraperformance liquid chromatography mass spectrometry to identify patients at high risk of early death, to identify patients who respond well to treatment, and to provide novel molecular insights into disease pathogenesis.

RESULTS: Fifty-three circulating metabolites distinguished well-phenotyped patients with idiopathic or heritable PAH (n=365) from healthy control subjects (n=121) after correction for multiple testing ($P < 7.3 \times 10^{-5}$) and confounding factors, including drug therapy, and renal and hepatic impairment. A subset of 20 of 53 metabolites also discriminated patients with PAH from disease control subjects (symptomatic patients without pulmonary hypertension, n=139). Sixty-two metabolites were prognostic in PAH, with 36 of 62 independent of established prognostic markers. Increased levels of tRNA-specific modified nucleosides (N²,N²-dimethylguanosine, N¹-methylinosine), tricarboxylic acid cycle intermediates (malate, fumarate), glutamate, fatty acid acylcarnitines, tryptophan, and polyamine metabolites and decreased levels of steroids, sphingomyelins, and phosphatidylcholines distinguished patients from control subjects. The largest differences correlated with increased risk of death, and correction of several metabolites over time was associated with a better outcome. Patients who responded to calcium channel blocker therapy had metabolic profiles similar to those of healthy control subjects.

CONCLUSIONS: Metabolic profiles in PAH are strongly related to survival and should be considered part of the deep phenotypic characterization of this disease. Our results support the investigation of targeted therapeutic strategies that seek to address the alterations in translational regulation and energy metabolism that characterize these patients.

Christopher J. Rhodes, PhD*
 Pavandeep Ghataorhe, BM, BCh*
 John Wharton, PhD
 Kevin C. Rue-Albrecht, PhD
 Charaka Hadinnapola, BM, BCh
 Geoffrey Watson, BM, BCh
 Marta Bleda, PhD
 Matthias Haimel, BSc
 Gerry Coghlan, MD
 Paul A. Corris, MD
 Luke S. Howard, DPhil
 David G. Kiely, MD
 Andrew J. Peacock, MD
 Joanna Pepke-Zaba, PhD
 Mark R. Toshner, MD
 S. John Wort, PhD
 J. Simon R. Gibbs, MD
 Allan Lawrie, PhD
 Stefan Gräf, PhD
 Nicholas W. Morrell, MD
 Martin R. Wilkins, MD

*Dr Rhodes and P. Ghataorhe contributed equally.

Correspondence to: Martin R. Wilkins, MD, Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Rd, London, W12 0NN, UK. E-mail m.wilkins@imperial.ac.uk

Sources of Funding, see page 472

Key Words: hypertension, pulmonary metabolism, metabolome, metabolomics, pulmonary circulation

© 2016 The Authors. *Circulation* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution License](#), which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Clinical Perspective

What Is New?

- This study provides a comprehensive analysis of circulating metabolite levels in patients with pulmonary arterial hypertension (PAH) and control subjects.
- It is the first study to relate metabolite levels to clinical outcomes in PAH.
- Increases in circulating modified nucleosides originating from transfer RNAs, energy metabolism intermediates, tryptophan, and polyamine metabolites and decreased steroids, sphingomyelins, and phosphatidylcholines independently discriminate patients with PAH from control subjects and predict survival.
- Correction of metabolite levels over time is linked to better clinical outcomes, and patients who respond well to calcium channel blocker therapy have metabolic profiles comparable to those of healthy control subjects.

What Are the Clinical Implications?

- Energy metabolism and stress-response pathways are disturbed in PAH.
- Monitoring plasma metabolites that report on these pathways over time could be useful to assess disease progression and response to therapy.
- Therapeutic strategies targeted against metabolic disturbances in PAH, particularly translational regulation and energy metabolism, merit further investigation.

Pulmonary arterial hypertension (PAH) is a progressive vascular disorder that leads to increased pulmonary vascular resistance, right ventricular dysfunction,¹ and premature death.² The pathogenesis of the vascular pathology is poorly understood.^{3,4} Several genetic mutations have been reported in hereditary and isolated idiopathic presentations of PAH, providing insight into perturbed signaling pathways,^{5,6} and genome sequencing of clinically well-characterized patient cohorts is underway in anticipation of finding new mutations. A complementary approach to identifying the molecular drivers of PAH is to conduct deep molecular phenotyping of patients beyond standard clinical tests.

Metabolomic technologies such as ultraperformance liquid chromatography mass spectrometry enable the detection and semiquantitative measurement of hundreds of unique metabolites, representing a broad range of metabolic pathways, in small volumes of biofluids.⁷ These approaches have identified differences in circulating metabolites that distinguish physiological and disease states such as diabetes mellitus and systemic cardiovascular disorders and predict clinical outcomes.^{8–10} So far, few metabolomics studies have been undertaken in patients with pulmonary vascular disease. Evidence of abnormal oxidation, arginine, and sphingosine pathways

has been found from mass spectrometry analysis of lung tissue from patients with PAH,^{11,12} and analysis of breath samples showed that exhaled volatile compounds discriminate between patients with severe idiopathic PAH and healthy volunteers.¹³ A targeted analysis of 105 circulating plasma metabolites in PAH, primarily amino acids, nucleosides, and their derivatives, showed that abnormal levels of tryptophan, purine, and tricarboxylic acid (TCA) cycle metabolites correlated to hemodynamic measures.¹⁴

In this study, we used a broad metabolomics platform to analyze 1416 metabolites in plasma from patients with idiopathic or heritable PAH ($n=365$) in 3 distinct cohorts and compared circulating levels with both healthy ($n=121$) and disease ($n=139$) control subjects. We identified specific metabolites that both discriminate patients with PAH from healthy and disease control subjects and independently predict survival. These metabolites included several modified nucleosides specific to transfer RNAs that indicate alterations in cell proliferation and translation of disease-related proteins, as well as several constituents of energy metabolism.

METHODS

Sample Collection

Samples were obtained from patients with idiopathic or heritable PAH attending the National Pulmonary Hypertension Service at Hammersmith Hospital, London, between 2002 and 2015 and from patients recruited from other UK national centers as part of the National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension (ClinicalTrials.gov. Unique identifier: NCT01907295). Control plasma samples were obtained from healthy subjects and disease control subjects, the latter being symptomatic patients presenting to the service but in whom pulmonary hypertension was excluded by cardiac catheterization. The diagnosis of PAH was based on standard criteria from the most recent guidelines.¹ Vasoresponders were defined as those whose mean pulmonary artery pressure dropped >10 mmHg to <40 mmHg with preserved cardiac output in response to an acute pulmonary vasodilator challenge and remained stable on calcium channel blocker therapy alone for at least 1 year.¹ Whole-genome sequencing data from the UK National Institute of Health Research BRIDGE consortium (Biomedical Research Centres Inherited Diseases Genetic Evaluation) were used to determine which patients had known pathogenic mutations in the gene encoding the bone morphogenetic protein type II receptor (*BMPRII*).⁵

Venous blood samples were drawn from the antecubital fossa and collected in EDTA Vacutainer tubes (BD, Oxford, UK), immediately put on ice, centrifuged (1300g, 15 minutes) within 30 minutes, and stored at -80°C until required. World Health Organization functional class and 6-minute walk distance at the sample date and clinical biochemical data (within 30 days) were recorded. All subjects provided informed written consent, and local research ethics committees approved the study. A subset of patients consented to provide additional samples at later dates while attending follow-up clinical appointments.

Metabolomics

Metabolomic profiling by ultraperformance liquid chromatography mass spectrometry was conducted by Metabolon (Durham, NC),⁷ which provided semiquantitative assessment of 949 named and 467 unnamed metabolite levels, annotated with pathways. Named compounds identified from mass and fragmentation analysis but yet to be confirmed with standards are indicated by asterisks. Details can be found in the [online-only Data Supplement](#).

Angiogenin

Plasma angiogenin levels were determined by ELISA (reference No. DANO, R&D Systems, Abingdon, UK) per the manufacturer's guidelines, with EDTA plasma diluted 1:800 before assay.

Statistical Analysis

To prevent skewing of results by outliers, initial group comparisons between control subjects and patients were performed with nonparametric Mann Whitney *U* tests. Before modeling, metabolites with distributions that were not normal were either transformed by log₁₀ or power transformations (x^Y , with *Y* from −2 to 2 in 0.5 steps, as performed for Box-Cox transformations¹⁵), whichever best normalized the data on the basis of Kolmogorov-Smirnov tests, or ranked if no test met $P>0.05$. Samples for which metabolites were undetected were imputed with the minimum detected level for the metabolite. Data in all groups were *z* score transformed on the basis of the mean and standard deviation in all healthy control subjects for ease of comparisons. Data are presented as absolute numbers, percentages, or mean or median (\pm SD) and percentile range.

Linear regression analysis was conducted to assess the relationships between metabolite levels, diagnoses, and potential confounders to determine whether differences in metabolite levels between groups were independent of age, sex, ethnicity, body mass index, drugs, and renal and hepatic dysfunction. In the disease control and PAH cohorts, preserved renal function was defined as creatinine <75 μ mol/L, and preserved liver function was defined as bilirubin <21 μ mol/L. Logistic regression was conducted to determine metabolites that independently distinguished between diagnostic groups. Orthogonal partial least squares discriminant analysis modeling was used to test the performance of these metabolites. R^2 scores indicate model performance, and Q^2 scores estimate reproducibility on the basis of cross-validation (subjects were divided into 7 groups, and their diagnosis was predicted on the basis of the other subjects in 7 analyses). Pathway enrichment analysis was conducted on discriminating and prognostic metabolites with the Fisher's exact test.

All survival analyses were performed with the use of time from sampling to death/census. Cox regression analysis was used to identify prognostic predictors, with proportional hazard assumptions tested and Kaplan-Meier plots used to illustrate events from time of sampling in relation to metabolite levels. Receiver-operating characteristic curves were used to assess discriminating and prognostic values of metabolites against diagnosis and all-cause mortality, respectively. Hierarchical clustering on the basis of euclidean distances was used to assess whether metabolites and patients clustered by functional pathways and phenotypes, respectively.

Network analysis was performed by calculating second-order Spearman rank correlations with ParCorA^{16,17} and visualized with Cytoscape.¹⁸ "Hub" nodes are metabolites with the most "edges" (correlations) to other metabolites.

Statistical analysis was performed with IBM SPSS Statistics 22 (International Business Machines Corp, New York, NY), Matlab (Matrix Laboratory, MathWorks, Natick, MA), Microsoft Excel (Microsoft, Redmond, WA), SIMCA-P software, (Umetrics, Umea, Sweden), and R with RStudio and associated packages.¹⁹

RESULTS

Metabolites Distinguishing Between PAH and Control Subjects

We first compared plasma metabolite profiles from 116 consecutive patients with idiopathic or heritable PAH attending Hammersmith Hospital between November 2011 and August 2013 and 58 healthy control subjects (Table 1). To minimize confounding factors, only patients with PAH who were 19 to 70 years of age were compared with age- and sex-matched healthy control subjects in this analysis. Results were validated in 75 patients with PAH recruited between 2002 and 2015 against a separate control group ($n=63$). A second validation analysis used 174 patients with PAH recruited from other specialist centers in the United Kingdom from August 2013 to June 2015 and compared with all control subjects. Metabolites identified as xenobiotics or detected in $<95\%$ of samples were excluded from the analysis, leaving 686 well-quantified biological metabolites.

Circulating levels of 97 metabolites distinguished PAH from healthy subjects in all 3 analyses after Bonferroni correction ($P<7.3e-5$). Of these metabolites, 53 distinguished healthy control and PAH subjects after correction for potential confounders, including age, sex, ethnicity, body mass index, creatinine, bilirubin, and drug therapies ($P<0.05$; [Table I in the online-only Data Supplement](#) and Figure 1). The most common confounders associated with metabolite levels were liver function (bilirubin) and renal function (creatinine). To determine whether these metabolite differences could be detected before the initiation of PAH therapies, we performed a subanalysis comparing 40 patients who were treatment naïve at the time of sampling, and all 53 metabolites distinguished this group from healthy control subjects ($P<0.05$; [Table I in the online-only Data Supplement](#)). Patients with pathogenic *BMP2* mutations ($n=42$) had metabolite levels similar to PAH patients without these mutations ([Figure I and Table I in the online-only Data Supplement](#)).

Given that many metabolic alterations might occur in a chronic disease such as PAH, we set out to prioritize more disease-specific metabolites by comparing the patients with PAH with disease control subjects, the latter comprising symptomatic patients in whom pulmonary

Table. Cohort Characteristics

	Discovery				Validation 1			Validation 2
	HCs (n=58)	DCs (n=70)	PAH (19–70 y) (n=88)	PAH (>70 y) (n=28)	HCs (n=63)	DCs (n=69)	PAH (n=75)	PAH-2 (n=174)
Age at sampling, y	48±13.5	56.5±15.9	48.1±13.8	75.9±4.8	49.1±16.1	55.9±18.5	52±16.3	52±15
Female:male (ratio)	38:20 (1.9:1)	48:22 (2.2:1)	61:27 (2.3:1)	19:9 (2.1:1)	40:23 (1.7:1)	48:21 (2.3:1)	52:23 (2.3:1)	127:47 (2.7:1)
Ethnicity, % nonwhite	32.5	56.9	17.0	14.8	38.1	44.1	18.6	8.1
BMI, kg/m ²	30.5±10.5	27.9±6	28.7±8.2	27.9±5.7	26±4.1	27.4±5.9	30.1±7.2	29.2±7
Baseline hemodynamics at diagnosis								
Pulmonary capillary wedge pressure, mm Hg		11.6±4.5	11.9±6	12.1±4.6		10.8±3.5	10.8±4.9	9.4±3.8
Mean pulmonary artery pressure, mm Hg		19.3±4.1	53.1±14.3	46.3±14.6		19.1±4.7	53.7±11.1	56.2±15.2
Pulmonary vascular resistance, Woods units			12.3±5.7	8.6±4.7			12.4±5.8	13±6.4
Mean right atrial pressure, mm Hg		7.3±3.4	10.0±5.7	9.3±4.9		6.3±3.2	11.8±5.8	9.2±5.3
Cardiac output, L/min			4.4±1.7	4.5±1.8			4.0±1.7	4.0±1.3
Functional status and pathology								
6-min walk distance, m			279.4±153.4	197.9±158.7			271.3±169.5	334.8±119.0
WHO functional class I/II/III/IV			2/11/65/10	0/2/23/1			0/7/52/9	2/24/119/18
RDW, %			14.8±2.1	15.0±1.1			16.0±2.9	14.7±3.3
NT-proBNP, pmol/L			735±882	1137±1123				895±1244
Creatinine, μmol/L		76.3±21.8	81.2±29.1	107.6±35.7		87±40.6	92.7±32.6	89.9±25.1
Bilirubin, μmol/L		13.9±13.9	15.6±10.7	12.4±8.5		16.3±22.8	17.2±10.4	12.1±9.0
Comorbidities (%)								
Asthma/COPD		17.1	11.4	11.1		11.6	17.1	17.6
Diabetes mellitus		8.6	17.0	48.1		13.0	24.3	14.2
CAD/IHD		10.0	12.5	37.0		11.6	12.9	8.3
AF/flutter		14.3	18.2	25.9		17.4	8.6	5.9
Systemic hypertension		22.9	19.3	77.8		36.2	22.9	17.2
Hypercholesterolemia/lipidemia		12.9	12.5	22.2		10.1	15.7	6.5
Drug therapy (%)								
Anticoagulation		32.9	71.6	78.6		34.8	65.3	66.7
PDE5 inhibitors		0.0	65.9	67.9		0.0	48.0	77.8
ERAs		0.0	48.0	30.8		0.0	33.8	64.3
Diuretics		12.9	37.5	75.0		21.7	53.3	54.4
Aldosterone antagonists		7.1	31.8	21.4		1.4	34.7	8.2
Statins/lipid-lowering drugs		25.7	22.7	57.1		33.3	24.0	24.0

(Continued)

Table. Continued

	Discovery				Validation 1			Validation 2
	HCs (n=58)	DCs (n=70)	PAH (19–70 y) (n=88)	PAH (>70 y) (n=28)	HCs (n=63)	DCs (n=69)	PAH (n=75)	PAH-2 (n=174)
CCBs		10.0	14.8	28.6		24.6	14.7	21.1
Cardiac glycosides		7.1	17.0	14.3		8.7	21.3	9.4
Antidiabetic drugs		8.6	12.5	35.7		10.1	18.7	9.4
Prostanoids		0.0	9.1	0.0		0.0	6.7	33.3
Iron replacement therapy		4.3	13.6	25.0		5.8	4.0	10.5
ACE inhibitors		27.1	17.0	60.7		37.7	28.0	16.4

Mean±SD, counts or percentages are given. ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; DC, disease control; ERA, endothelin receptor antagonist; HC, healthy control; IHD, ischemic heart disease; NT-proBNP, N-terminal brain natriuretic peptide at time of sample; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase 5; RDW, red cell distribution width; and WHO, World Health Organization. Ethnicity is shown for subjects who self-declared.


hypertension had been excluded. We again adopted a discovery-and-validation design with 2 groups of disease control subjects (n=70 and 69). A subset (20 of 53) of the metabolites distinguished patients with PAH from disease control subjects after correction for potential confounders ($P<0.05$; Table 1 in the online-only Data Supplement). These “PAH-specific” differences in metabolites included increases in purine, polyamine, and TCA cycle metabolites and decreases in phosphocholines and sphingomyelins (Figure 2A), with network analysis showing the importance of hub metabolites N2,N2-dimethylguanosine and malate (Figure 2B).

Discriminant Analyses to Distinguish PAH and Control Groups

To identify a minimal set of metabolites that could in combination best distinguish patients with PAH, we

performed logistic regression analysis. We found that 7 of 53 metabolites—dehydroisoandrosterone sulfate (DHEA-S), methionine sulfone, N1-methylinosine, oleoyl-carnitine, palmitoylcholine, sphingomyelin (d18:1/20:0, d16:1/22:0)*, and X-24513—independently distinguished patients with PAH (19–70 years of age) and healthy subjects in the discovery analysis with 90% accuracy in an orthogonal partial least squares discriminant analysis ($R^2=0.64$, $Q^2=0.61$). This model classified healthy subjects and patients with PAH in the 2 validation analyses with 89% and 84% accuracy, respectively. In addition, 90% (9 of 10) of PAH vasoresponders in the discovery cohort had metabolite levels typical of healthy control subjects (Figure 3A and 3B).

Four of the 20 PAH-specific metabolites—N-acetylaspartate, octadecanedioate, palmitoylcholine, and X-13737—distinguished patients with PAH and disease control subjects with 83% accuracy in the discovery

**Figure 1. Analysis flow chart.**

Summary of analytic workflow showing numbers of metabolites that distinguish patients with pulmonary arterial hypertension (PAH) from control subjects and/or are prognostic in PAH. NT-proBNP indicates N-terminal brain natriuretic peptide; and RDW, red cell distribution width.




Figure 2. Metabolites that discriminate patients with pulmonary arterial hypertension (PAH) from control subjects.

A, Average metabolite levels in PAH and control subjects for 20 metabolites found to significantly distinguish patients with PAH from both healthy and disease control subjects independently of potential confounders. Values plotted are z scores calculated from the mean and standard deviation of all healthy volunteers in the study. Negative values indicate metabolites at lower levels in patients vs healthy control subjects, and positive values indicate higher levels of metabolites in patients. For the discovery analysis, only data from patients with PAH who were 19 to 70 years of age are plotted; for the validation analysis, all patients data are shown. **B**, Network analysis of the same 20 metabolites on the basis of second-order correlations. Line thickness indicates strength of correlations (all $P < 0.0001$). *Probable metabolite identity but unconfirmed (see Methods). DHE indicates docosahexaenoyl; DHEA-S, dehydroisoandrosterone sulfate; DPE, docosapentaenoyl; EPE, eicosapentaenoyl; GPC, glycerophosphocholine; and SM, sphingomyelin.




Figure 3. Discriminant analysis models on the basis of low numbers of metabolites distinguish patients with pulmonary arterial hypertension (PAH) from control subjects. **A** and **C**, Dot plots showing individual subjects' model scores for healthy control subjects (HC), patients with PAH, vasore-sponders, and disease control subjects (DC) in discovery and validation analyses. Metabolites were selected by logistic regres-sion of PAH-HC (**A**) and PAH-DC (**C**) comparisons. **B** and **D**, Receiver-operating characteristic curves showing the performance of models in distinguishing PAH from HC (**B**) and DC (**D**) subjects. AUC indicates area under the curve; and CI, confidence interval.

analysis ($R^2=0.49$, $Q^2=0.47$). This model classified dis-ease control subjects and patients with PAH in the 2 validation analyses with 69% and 67% accuracy, respec-tively (Figure 3C and 3D).

Survival Analysis of Plasma Metabolites of Interest in PAH

We hypothesized that metabolites most closely related to the disease pathobiology would be associated with clinical outcomes. To identify metabolites associated with disease progression and mortality, we performed survival analy-ses. Twenty-eight of 116 and 25 of 75 patients died in the discovery and first validation PAH groups with an average follow-up of 3.3 ± 1.0 and 4.5 ± 4.0 years, respectively.

The length of patient follow-up in the second validation cohort was insufficient to permit analysis. After correcting for creatinine and diuretic use, no other potentially con-founding factor was associated with survival. Of the 686 well-quantified metabolites, 640 met the assumptions of Cox regression analysis, and 62 of these were prognostic after accounting for creatinine and diuretic use in both analyses. Receiver-operating characteristic analysis at 3 years of follow-up confirmed that these metabolites were prognostic and identified optimal cutoffs ($P<0.05$; [Figure II in the online-only Data Supplement](#)). To identify metabolites that report on novel pathways independently of current prognostic estimates, we com-pared the 62 prognostic metabolites with 3 markers previously found to best predict survival in our patients,

namely N-terminal brain natriuretic peptide, 6-minute walk distance, and red cell distribution width.²⁰ Thirty-six of 62 of the metabolites were independent of these measures ($P<0.05$; Figure 4A and Table II in the online-only Data Supplement), and network analysis indicated 2 main clusters with hub metabolites, including again, among others, N2,N2-dimethylguanosine (Figure 4B).

Enrichment and Clustering of Metabolites of Interest

The above analyses identified and validated, after controlling for confounders, a total of 99 metabolites that were either discriminating or prognostic in PAH, representing 25 metabolic pathways. Six pathways in particular were enriched with metabolites of interest, including fatty acid (acyl carnitines), polyamine, and nucleoside metabolism ($P<0.05$; Table III in the online-only Data Supplement). Sixteen of these metabolites both discriminated PAH and were prognostic; these, along with the 3 other metabolites selected by logistic regression modeling to best distinguish patients with PAH and healthy subjects, clustered into defined metabolic pathways (Figure 5).

Analysis of Serial Samples

Changes in metabolite levels in individuals over time may indicate pathways that report clinical improvement or the correction of which leads to improved outcomes. We analyzed serial samples from 86 patients who were followed up for a minimum of 1 year (median, 1.50 years; interquartile range, 1.33–2.95 years) after the second sample. Twenty-nine patients died during follow-up. Changes in metabolite levels between the 2 samples (median time between samples, 1.75 years; interquartile range, 1.07–2.58 years) were compared between survivors and nonsurvivors.

Changes in 27 of 99 metabolites, including several modified amino acids and nucleosides, were significantly different between survivors and nonsurvivors ($P<0.05$). Receiver-operating characteristic analysis confirmed these associations (Table IV in the online-only Data Supplement) and identified prognostic cut-offs (Figure 6).

Association of Elevated Modified Nucleosides With Elevated Plasma Angiogenin

Modified nucleosides can be released into the circulation during stress after cleavage of transfer RNAs (tRNAs) by the ribonuclease angiogenin.²¹ To determine whether this mechanism was relevant to PAH, we measured plasma angiogenin in a representative subset of age- and sex-matched healthy control subjects and patients with PAH from the discovery analysis (Table V in the online-only Data Supplement). Angiogenin levels were elevated in plasma from patients with PAH and correlated with N2,N2-dimethylguanosine levels ($\rho=0.49$, $P<0.001$; Fig-

ure 7). The strength of correlation was similar in male and female subjects (data not shown).

DISCUSSION

This study represents the most comprehensive analysis of circulating metabolites in patients with PAH to date. It is the first to robustly identify and validate differences in comparison to both healthy and symptomatic disease control subjects without pulmonary hypertension and to associate metabolic profiles with outcomes in PAH, strengthening the evidence that the pathways identified could be important modifiers of disease progression. Changes in the levels of metabolites over time were associated with survival in a direction that suggests that correction of these disturbances is linked to improved outcomes. In agreement with this, patients defined as vasoresponders, who have excellent outcomes on calcium channel blocker therapies, demonstrated metabolic profiles more similar to those of healthy control subjects than to other patients. Metabolic profiles seen in incident cases were similar to those with established PAH, emphasizing that metabolic dysregulation is not corrected in the majority of cases by current therapy.

Modified Nucleosides

Two of the most robust distinguishing and prognostic differences identified in patients with PAH were increased levels of N1-methylinosine and N2,N2-dimethylguanosine. These are recognized epigenetic, posttranscriptional modifications of tRNA,^{21–23} and other tRNA modifications also found to be increased and prognostic included pseudouridine, N6-carbamoylthreonyl-adenosine and N1-methyladenosine. N2,N2-dimethylguanosine is found in the majority of tRNAs at position 26, upstream of the anticodon sequence at positions 34 to 36, and promotes the folding of tRNAs toward the classical cloverleaf structure.²⁴ N1-methylinosine is found 3' adjacent to the anticodon at position 37 of eukaryotic tRNAs and is formed from inosine by a specific S-adenosylmethionine-dependent methylase.²⁵ Increased serum and urine levels of N2,N2-dimethylguanosine, as well as pseudouridine and 1-methylinosine, have been observed in multiple solid tumor malignancies²⁶ and may reflect the general upregulation of the translational apparatus, including tRNA turnover, in hyperproliferative cancerous cells.²⁷ Increased circulating 1-methyladenosine has also been shown to be an early indicator of oxidative stress, cell damage, and mortality in kidney disease.²⁸

Intracellular tRNA pools are dynamically regulated. For example, under stress, tRNAs required for the translation of stress response proteins are preferentially expressed.²¹ The altered levels of specific nucleoside modifications in patients with PAH may reflect preferential expression of the tRNAs that harbor them as part of a switch toward




Figure 4. Prognostic metabolites independent of established risk factors.
A, Hazard ratios after correction for creatinine and diuretic use of 36 metabolites that were prognostic in patients with pulmonary arterial hypertension independently of red cell distribution width, N-terminal brain natriuretic peptide, and 6-minute (Continued)

Figure 4 Continued. walk distance. Hazard ratios indicate the risk of a change in each metabolite of 1 SD for ease of comparison. Patients of all ages were included in both the discovery and validation survival analyses. **B**, Network analysis of the same 36 metabolites on the basis of second-order correlations. Line thickness indicates strength of correlations (all $P < 0.0001$). Red lines indicate negative correlations. *Probable metabolite identity but unconfirmed (see Methods). DHE indicates docosahexaenoyl; DHEA-S, dehydroisoandrosterone sulfate; DPE, docosapentaenoyl; EPE, eicosapentaenoyl; GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine; Met, Cys, SAM and Taur, methionine, cysteine, S-adenosylmethionine and taurine; and SM, sphingomyelin.

translation of disease-related proteins. In addition, stress-induced cleavage of tRNA produces fragments that propagate the stress response and interfere with eukaryotic initiation factors-4G and -4F.²¹ Furthermore, eukaryotic ini-

tiation factor-2 α kinase-4 (GCN2), which prevents eukaryotic initiation factor-2 α from interacting with the initiating Met-tRNA, suppressing general protein synthesis and activating stress-inducible transcription factors, is mutated




Figure 5. Hierarchical clustering of 19 discriminating and prognostic metabolites in patients with pulmonary arterial hypertension (PAH).

A, Venn diagram shows overlap between metabolites that discriminate patients with PAH from healthy control subjects in all 3 cohorts from logistic regression between patients with PAH and healthy control subjects and prognostic metabolites in the discovery and first validation cohorts. **B**, Clustering of the 19 overlapping metabolites from **A** is shown between healthy control subjects (HC; n=58), PAH survivors (n=110, alive at 3 years after sample), and nonsurvivors (n=24) in the discovery analysis. Red indicates metabolite levels that are increased (and blue levels that are decreased) in patients with PAH vs control subjects. *Probable metabolite identity but unconfirmed (see Methods). ‡Metabolites also distinguish PAH from disease control subjects. DHEA-S indicates dehydroisoandrosterone sulphate; EPE, eicosapentaenoyl; GPC, glycerophosphocholine; and SM, sphingomyelin.




Figure 6. Analysis of serial samples.

A, Receiver-operating characteristic analysis of changes in metabolite levels and survival status at last follow-up. **B** and **D**, Changes in individual patient metabolite levels grouped by survival status at last follow-up. **C**, Kaplan-Meier analysis illustrating survival over time in patients with pulmonary arterial hypertension divided into groups according to the changes in N-acetyl-methionine levels between serial samples.

and causally implicated in some cases of pulmonary vascular disease.²⁹ Mutations in tRNA genes themselves have also been reported to cause pulmonary hypertension driven by mitochondrial dysfunction.³⁰

The initial cleavage of tRNAs is mediated by angiogenin,²¹ which we showed to be elevated in the plasma of patients with PAH in concert with elevated levels of modified nucleosides. Angiogenin is also upregulated in cancer cells, mediating angiogenesis, cell proliferation, and protection from apoptosis,³¹ and is increased in breath condensates from patients with pulmonary hypertension,³² indicating a possible pulmonary origin in this disease. Angioproliferative plexiform vascular lesions are characteristic of advanced PAH, and the proangiogenic activity of angiogenin is inhibited by mutation of its ribonuclease active site,³³ suggesting that elevated angiogenin and nucleoside levels may report patients developing this type

of pulmonary vascular remodeling. Alterations in tRNA biology appear to be capable of driving the development of rare forms of pulmonary hypertension and are closely linked to the progression of PAH. Circulating levels of modified nucleosides may reflect increases in both pulmonary vascular cell proliferation and stress.

Energy Metabolism

Significant alterations were observed in several pathways related to cellular energy production, with accumulation of multiple acylcarnitines, glutamate, and TCA cycle intermediates. Their accumulation in patients with PAH may represent a failed attempt to increase utility of fatty acids as an energy source, perhaps reflecting the inability of fatty acid beta-oxidation to keep pace with the demands of the overburdened right ventricle. Gluta-




Figure 7. Circulating angiogenin levels.

A, Plasma angiogenin levels determined by ELISA in healthy control subjects and patients with PAH. **B**, Scatterplot of plasma N2,N2-dimethylguanosine vs plasma angiogenin in control subjects and patients with pulmonary arterial hypertension (PAH). Statistics shown are from the Spearman rank test.

minolysis is another alternative energy production pathway to glucose oxidation, with the product glutamate entering the TCA cycle as α -ketoglutarate. Inhibition of glutaminolysis and restoration of glucose oxidation have beneficial effects in rat models of right ventricular hypertrophy.³⁴ Increased circulating glutamate levels have previously been seen in cancer patients³⁵; however, antiglutaminolysis therapeutic targets have demonstrated toxic side effects.³⁶ The buildup of TCA intermediates and the precursors to the molecules that enter the cycle (acylcarnitines and glutamate) may indicate dysfunction of this cycle, or at least the inability to keep pace with the demands of the most active cells such as proliferating pulmonary vascular cells. Increased levels of citrate, succinate, and fatty acid metabolites have been demonstrated in lung tissue from patients with PAH,¹¹ suggesting that dysfunctional energy metabolism is a feature of the diseased tissue. Restoration of glucose oxidation by dichloroacetate therapy is under investigation as a treatment for PAH (ClinicalTrials.gov. Unique identifier: NCT01083524),³⁷ and maximizing the capacity of the TCA cycle to process the acetyl-CoA produced may be a complementary therapeutic approach.

Consistent with previous reports, we found a significant increase in the circulating levels of long-chain acylcarnitines (oleoylcarnitine)³⁸ and short-chain (myristoylcarnitine, acetylcarnitine, hydroxybutyrylcarnitine) and medium-chain (adipoylcarnitine, suberoylcarnitine) products. The accumulation of acylcarnitines may itself be detrimental, effecting cardiac electrophysiological changes and arrhythmias.³⁹ There is also increasing evidence that accumulation of long-chain acylcarnitines may contribute to insulin resistance,⁴⁰ which is itself common and associated with prognosis in PAH.⁴¹

Lipids, Steroids, Polyamines, and Tryptophan Metabolites

Multiple sphingomyelin and phosphatidylcholine lipid species were significantly reduced in patients with PAH, relating to increased mortality. Sphingomyelins are the most abundant subclass of sphingolipids, with other subclasses including sphingosines, ceramides, and glycosphingolipids.⁴² In patients with chronic obstructive pulmonary disease, low plasma levels of several sphingomyelins relate to disease severity.⁴³ As a membrane constituent, sphingomyelins are implicated in transmembrane signaling and are generated from phosphatidylcholine and ceramide by sphingomyelin synthase, the knockout of which leads to mitochondrial dysfunction and reduced insulin release.⁴⁴ Sphingomyelins may also be considered a source of ceramide, which directly (and indirectly through other active lipid products) regulates cell proliferation, apoptosis, cell migration, and autophagy.⁴⁵

Reduced lineoyl-glycerophosphocholine has been shown to be an early marker of insulin resistance in non-diabetics,⁴⁶ and decreased circulating levels of several phosphatidylcholines were seen in patients with severe heart failure.⁴⁷ Phospholipids are also sources of multiple cellular signaling molecules, including eicosanoids such as prostacyclin,⁴⁸ levels of which are known to be reduced in pulmonary hypertension, with replacement an established treatment option.

Circulating levels of DHEA-S and its metabolites (androsterone, epiandrosterone, and androstenediol/4-androsten-3 β , 17 β -diol disulfate) were reduced in patients with PAH compared with healthy control subjects, consistent with a recent report of reduced circulating levels of DHEA-S in a small cohort of 23

male patients with PAH compared with healthy control subjects.⁴⁹ Differences in DHEA-S between patients with PAH and control subjects were independent of the more subtle effects of both sex and age (Figure III in the online-only Data Supplement), and lower DHEA-S levels were independently associated with mortality. Treatment with DHEA or DHEA-S has repeatedly been shown to prevent and reverse pulmonary hypertension in experimental rat models,⁵⁰ with clinical trials ongoing in chronic obstructive pulmonary disease–associated pulmonary hypertension (ClinicalTrials.gov. Unique identifier: NCT00581087).

We found increased levels of a breakdown product of N1-acetylspermidine, acisoga. Other metabolites of polyamine metabolism (4-acetamidobutanoate and N-acetylputrescine) were increased in PAH in relation to bilirubin levels and were prognostic in 2 distinct PAH cohorts, independently of established prognostic markers. Several animal models of pulmonary hypertension have demonstrated evidence of increased polyamine levels and metabolism in lung tissue.⁵¹ Administration of monocrotaline to rats led to significantly increased levels of polyamines and the development of pulmonary hypertension and right ventricular hypertrophy, which could be prevented by the administration of an inhibitor of polyamine biosynthesis,⁵² suggesting that these molecules may be novel therapeutic targets.

In our study, we validated findings of elevated circulating tryptophan metabolites¹⁴ with increased C-glycosyltryptophan and kynurenine in patients with PAH compared with healthy control subjects, but changes in kynurenine were related to increased bilirubin levels and liver dysfunction. Levels of tryptophan and its other major metabolite, serotonin, were not significantly altered in our analysis.

Limitations

The majority of patients included in this study were patients with prevalent disease on established treatments. A subanalysis conducted with 40 patients with incident disease showed similar results. Corrections were also made for potential treatment effects in the main analyses, including PAH-specific and comorbidity-related therapies, as well as demographics and renal/hepatic function.

Patients and control subjects were sampled in the nonfasting state, and information on insulin resistance was not available for all participants. Patients were also sampled from a peripheral vein. The stronger performance of discriminating models in discovery analyses suggests that optimization could further improve their performance in distinct cohorts. Strongly correlated metabolites would not have been selected in the discriminant modeling, so each metabolite used in the final models may represent clusters of multiple metabolites.

Evidence of tissue specificity and the source of circulating metabolites in pulmonary hypertension require further studies, for example, by transpulmonary sampling and direct measurements from tissue samples, to better localize the source of informative metabolites. Plasma levels of metabolites may not reflect levels in the most important tissues; for example, increased bile acid metabolites have been demonstrated in PAH lung tissue,⁵³ but no differences were seen in circulating levels in our study.

Summary and Conclusions

Increased circulating modified nucleosides (N2,N2-dimethylguanosine, N1-methylinosine), TCA cycle intermediates (malate, fumarate), glutamate, fatty acid acylcarnitines, and polyamine metabolites and decreased levels of steroids, sphingomyelins, and phosphatidylcholines are characteristics of patients with PAH that distinguish them from symptomatic patients without pulmonary hypertension. Improvements in circulating metabolite levels are associated with a better prognosis and could be used to monitor response to PAH treatments. Indeed, our results support the investigation of therapeutic strategies targeted at alterations in energy metabolism in PAH and suggest options for correcting translational regulation that also merit further study.

ACKNOWLEDGMENTS

This article presents independent research that was supported by the National Institute for Health Research (NIHR)/Wellcome Trust Imperial Clinical Research Facility at Imperial College Healthcare NHS Trust, London, UK. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The authors are indebted to Souad Ali and Sharon Meehan for blood sample collection and to Abdul Mulla, George Villas, Lavanya Ranganathan, and the TRIPHIC (Translational Research in Pulmonary Hypertension at Imperial College) system for the processing and pseudonymization of patient information. The authors also thank all the staff and participants of the BRIDGE (BioResource–Rare Diseases) and the National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension for their invaluable and ongoing contributions.

SOURCES OF FUNDING

Dr Rhodes is supported by a British Heart Foundation (BHF) Intermediate Basic Science Research Fellowship (FS-15-59-31839) and Dr Lawrie by a BHF Senior Basic Science Fellowship (FS/13/48/30453). Dr Wilkins is supported by a BHF program grant (RG/10/16/28575). Dr Morrell is an NIHR senior investigator. This research was also supported by a BHF Special Project (SP/12/12/29836), MRC Experimental Challenge Award (MR/K020919/1), the NIHR Bioresource for Rare Diseases, Imperial College and Cambridge NIHR Biomedical

Research Centres, and the NIHR Rare Diseases Translational Research Collaboration.

DISCLOSURES

None.

AFFILIATIONS

From the Department of Medicine, Imperial College London, Hammersmith Campus, United Kingdom (C.J.R., P.G., J.W., K.C.R.-A., G.W., M.R.W.); Department of Medicine, University of Cambridge School of Clinical Medicine, United Kingdom (C.H., M.B., M.H., M.R.T., S.G., N.W.M.); Cardiology Department, Royal Free Hospital, London, United Kingdom (G.C.); Institute of Cellular Medicine, Newcastle University and the Newcastle Upon Tyne Hospitals NHS Foundation Trust, United Kingdom (P.A.C.); National Pulmonary Hypertension Service, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom (L.S.H., J.S.R.G.); National Heart and Lung Institute, Imperial College London, Hammersmith Campus, United Kingdom (L.S.H., J.S.R.G.); Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, United Kingdom (D.G.K.); Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, United Kingdom (D.G.K., A.L.); Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.J.P.); Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, United Kingdom (J.P.Z., M.R.T.); Pulmonary Hypertension Service, Royal Brompton Hospital, London, United Kingdom (S.J.W.); and Department of Haematology, University of Cambridge, United Kingdom (S.G.).

FOOTNOTES

Received July 21, 2016; accepted November 9, 2016.

The online-only Data Supplement is available with this article at <http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.116.024602/-/DC1>.

Circulation is available at <http://circ.ahajournals.org>.

REFERENCES

1. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS); endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Respir J*. 2015;46:903–975. doi: 10.1183/13993003.01032-2015.
2. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. *Chest*. 2012;142:448–456. doi: 10.1378/chest.11-1460.
3. Ryan JJ, Archer SL. Emerging concepts in the molecular basis of pulmonary arterial hypertension, part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. *Circulation*. 2015;131:1691–1702. doi: 10.1161/CIRCULATIONAHA.114.006979.
4. Maron BA, Leopold JA. Emerging concepts in the molecular basis of pulmonary arterial hypertension, part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension. *Circulation*. 2015;131:2079–2091. doi: 10.1161/CIRCULATIONAHA.114.006980.
5. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips JA 3rd, Soubrier F, Trembath RC, Chung WK. Genetics and genomics of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009;54(suppl):S32–S42. doi: 10.1016/j.jacc.2009.04.015.
6. Ma L, Chung WK. The genetic basis of pulmonary arterial hypertension. *Hum Genet*. 2014;133:471–479. doi: 10.1007/s00439-014-1419-3.
7. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. *Anal Chem*. 2009;81:6656–6667. doi: 10.1021/ac901536h.
8. Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, Shi X, Deo R, Roth FP, Asnani A, Rhee EP, Systrom DM, Semigran MJ, Vasan RS, Carr SA, Wang TJ, Sabatine MS, Clish CB, Gerszten RE. Metabolic signatures of exercise in human plasma. *Sci Transl Med*. 2010;2:33ra37. doi: 10.1126/scitranslmed.3001006.
9. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. *Nat Med*. 2011;17:448–453. doi: 10.1038/nm.2307.
10. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. *Circulation*. 2012;126:1110–1120. doi: 10.1161/CIRCULATIONAHA.111.060368.
11. Zhao Y, Peng J, Lu C, Hsin M, Mura M, Wu L, Chu L, Zamel R, Machuca T, Waddell T, Liu M, Keshavjee S, Granton J, de Perrot M. Metabolomic heterogeneity of pulmonary arterial hypertension. *PLoS One*. 2014;9:e88727. doi: 10.1371/journal.pone.0088727.
12. Zhao YD, Chu L, Lin K, Granton E, Yin L, Peng J, Hsin M, Wu L, Yu A, Waddell T, Keshavjee S, Granton J, de Perrot M. A biochemical approach to understand the pathogenesis of advanced pulmonary arterial hypertension: metabolomic profiles of arginine, sphingosine-1-phosphate, and heme of human lung. *PLoS One*. 2015;10:e0134958. doi: 10.1371/journal.pone.0134958.
13. Mansoor JK, Schelegle ES, Davis CE, Walby WF, Zhao W, Aksenov AA, Pasamontes A, Figueroa J, Allen R. Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension. *PLoS One*. 2014;9:e95331. doi: 10.1371/journal.pone.0095331.
14. Lewis GD, Ngo D, Hemnes AR, Farrell L, Doms C, Pappagianopoulos PP, Dhakal BP, Souza A, Shi X, Pugh ME, Beloiartsev A, Sinha S, Clish CB, Gerszten RE. Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension. *J Am Coll Cardiol*. 2016;67:174–189. doi: 10.1016/j.jacc.2015.10.072.
15. Box G, Cox D. An analysis of transformations. *J Royal Stat Soc*. 1964;26:211–252.
16. Mendes Research Group Web site. <http://www.comp-sys-bio.org/software.html>. Accessed March 1, 2016.
17. de la Fuente A, Bing N, Hoeschele I, Mendes P. Discovery of meaningful associations in genomic data using partial correlation coefficients. *Bioinformatics*. 2004;20:3565–3374.

18. Cytoscape. <http://www.cytoscape.org/>. Accessed March 1, 2016.
19. The comprehensive R archive network. <http://CRAN.R-project.org/>. Accessed December 1, 2015.
20. Rhodes CJ, Wharton J, Howard LS, Gibbs JS, Wilkins MR. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. *Heart*. 2011;97:1054–1060. doi: 10.1136/hrt.2011.224857.
21. Kirchner S, Ignatova Z. Emerging roles of tRNA in adaptive translation, signalling dynamics and disease. *Nat Rev Genet*. 2015;16:98–112. doi: 10.1038/nrg3861.
22. Slotkin W, Nishikura K. Adenosine-to-inosine RNA editing and human disease. *Genome Med*. 2013;5:105. doi: 10.1186/gm508.
23. Torres AG, Batlle E, Ribas de Pouplana L. Role of tRNA modifications in human diseases. *Trends Mol Med*. 2014;20:306–314. doi: 10.1016/j.molmed.2014.01.008.
24. Steinberg S, Cedergren R. A correlation between N2-dimethylguanosine presence and alternate tRNA conformers. *RNA*. 1995;1:886–891.
25. Grosjean H, Auxilien S, Constantinesco F, Simon C, Corda Y, Becker HF, Foiret D, Morin A, Jin YX, Fournier M, Fourrey JL. Enzymatic conversion of adenosine to inosine and to N1-methylinosine in transfer RNAs: a review. *Biochimie*. 1996;78:488–501.
26. Waalkes TP, Gehrke CW, Zumwalt RW, Chang SY, Lakings DB, Tormey DC, Ahmann DL, Moertel CG. The urinary excretion of nucleosides of ribonucleic acid by patients with advanced cancer. *Cancer*. 1975;36:390–398.
27. Anderson P, Ivanov P. tRNA fragments in human health and disease. *FEBS Lett*. 2014;588:4297–4304. doi: 10.1016/j.febslet.2014.09.001.
28. Mishima E, Inoue C, Saigusa D, Inoue R, Ito K, Suzuki Y, Jinno D, Tsukui Y, Akamatsu Y, Araki M, Araki K, Shimizu R, Shinke H, Suzuki T, Takeuchi Y, Shima H, Akiyama Y, Toyohara T, Suzuki C, Saiki Y, Tominaga T, Miyagi S, Kawagishi N, Soga T, Ohkubo T, Yamamura K, Imai Y, Masuda S, Sabbisetti V, Ichimura T, Mount DB, Bonventre JV, Ito S, Tomioka Y, Itoh K, Abe T. Conformational change in transfer RNA is an early indicator of acute cellular damage. *J Am Soc Nephrol*. 2014;25:2316–2326. doi: 10.1681/ASN.2013091001.
29. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmueller P, Fadel E, Sitbon O, Simonneau G, Tregouët D, Humbert M, Soubrier F. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. *Nat Genet*. 2014;46:65–69. doi: 10.1038/ng.2844.
30. Sproule DM, Dyme J, Coku J, de Vinck D, Rosenzweig E, Chung WK, De Vivo DC. Pulmonary artery hypertension in a child with MELAS due to a point mutation of the mitochondrial tRNA(Leu) gene (m.3243A>G). *J Inher Metab Dis*. 2008;31(suppl 3):497–503. doi: 10.1007/s10545-007-0735-3.
31. Saikia M, Hatzoglou M. The many virtues of tRNA-derived stress-induced RNAs (tiRNAs): discovering novel mechanisms of stress response and effect on human health. *J Biol Chem*. 2015;290:29761–29768. doi: 10.1074/jbc.R115.694661.
32. Seyfarth HJ, Sack U, Gessner C, Wirtz H. Angiogenin, bFGF and VEGF: angiogenic markers in breath condensate of patients with pulmonary hypertension [in German]. *Pneumologie*. 2015;69:207–211. doi: 10.1055/s-0034-1391775.
33. Shapiro R, Vallee BL. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin: alanine derivatives inhibit angiogenin-induced angiogenesis. *Biochemistry*. 1989;28:7401–7408.
34. Piao L, Fang YH, Parikh K, Ryan JJ, Toth PT, Archer SL. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. *J Mol Med (Berl)*. 2013;91:1185–1197. doi: 10.1007/s00109-013-1064-7.
35. Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scio-neaux R, Subramani D, Manhardt C, Lorusso GD, Willard SS, Thompson H, Shourideh M, Rezaei K, Sartor O, Mohler JL, Vessella RL. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. *Clin Cancer Res*. 2012;18:5888–5901. doi: 10.1158/1078-0432.CCR-12-1308.
36. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. *Nat Rev Cancer*. 2010;10:267–277. doi: 10.1038/nrc2817.
37. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. *Circulation*. 2002;105:244–250. doi: 10.1161/hc0202.101974.
38. Brittain EL, Talati M, Fessel JP, Zhu H, Penner N, Calcutt MW, West JD, Funke M, Lewis GD, Gerszten RE, Hamid R, Pugh ME, Austin ED, Newman JH, Hemnes AR. Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. *Circulation*. 2016;133:1936–1944.
39. DaTorre SD, Creer MH, Pogwizd SM, Corr PB. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. *J Mol Cell Cardiol*. 1991;23(suppl 1):11–22.
40. Schooneman MG, Vaz FM, Houten SM, Soeters MR. Acylcarnitines: reflecting or inflicting insulin resistance? *Diabetes*. 2013;62:1–8. doi: 10.2337/db12-0466.
41. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M, Doyle RL. Insulin resistance in pulmonary arterial hypertension. *Eur Respir J*. 2009;33:318–324. doi: 10.1183/09031936.00000508.
42. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. *Nat Rev Mol Cell Biol*. 2008;9:139–150. doi: 10.1038/nrm2329.
43. Bowler RP, Jacobson S, Cruickshank C, Hughes GJ, Siska C, Ory DS, Petrache I, Schaffer JE, Reisdorph N, Kechris K. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. *Am J Respir Crit Care Med*. 2015;191:275–284. doi: 10.1164/rccm.201410-1771OC.
44. Yano M, Watanabe K, Yamamoto T, Ikeda K, Senokuchi T, Lu M, Kadamatsu T, Tsukano H, Ikawa M, Okabe M, Yamaoka S, Okazaki T, Umehara H, Gotoh T, Song WJ, Node K, Taguchi R, Yamagata K, Oike Y. Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. *J Biol Chem*. 2011;286:3992–4002. doi: 10.1074/jbc.M110.179176.
45. Taniguchi M, Okazaki T. The role of sphingomyelin and sphingomyelin synthases in cell death, proliferation and migration-from cell and animal models to human disorders. *Biochim Biophys Acta*. 2014;1841:692–703. doi: 10.1016/j.bbalip.2013.12.003.
46. Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari A, Adam KP, Milburn MV, Kastenmüller G, Adamski J, Tuomi T, Lysenko V, Groop L, Gall WE. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. *Diabetes*. 2013;62:1730–1737. doi: 10.2337/db12-0707.
47. Cheng ML, Wang CH, Shiao MS, Liu MH, Huang YY, Huang CY, Mao CT, Lin JF, Ho HY, Yang NI. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. *J Am Coll Cardiol*. 2015;65:1509–1520. doi: 10.1016/j.jacc.2015.02.018.
48. Wymann MP, Schneider R. Lipid signalling in disease. *Nat Rev Mol Cell Biol*. 2008;9:162–176. doi: 10.1038/nrm2335.

49. Ventetuolo CE, Baird GL, Barr RG, Bluemke DA, Fritz JS, Hill NS, Klinger JR, Lima JA, Ouyang P, Palevsky HI, Palmisciano AJ, Krishnan I, Pinder D, Preston IR, Roberts KE, Kawut SM. Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men. *Am J Respir Crit Care Med*. 2016;193:1168–1175. doi: 10.1164/rccm.201509-1785OC.
50. Alzoubi A, Toba M, Abe K, O'Neill KD, Rocic P, Fagan KA, McMurtry IF, Oka M. Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. *Am J Physiol Heart Circ Physiol*. 2013;304:H1708–H1718. doi: 10.1152/ajpheart.00746.2012.
51. Hoet PH, Nemery B. Polyamines in the lung: polyamine uptake and polyamine-linked pathological or toxicological conditions. *Am J Physiol Lung Cell Mol Physiol*. 2000;278:L417–L433.
52. Olson JW, Atkinson JE, Hacker AD, Altieri RJ, Gillespie MN. Suppression of polyamine biosynthesis prevents monocrotaline-induced pulmonary edema and arterial medial thickening. *Toxicol Appl Pharmacol*. 1985;81:91–99.
53. Zhao YD, Yun HZ, Peng J, Yin L, Chu L, Wu L, Michalek R, Liu M, Keshavjee S, Waddell T, Granton J, de Perrot M. De novo synthesis of bile acids in pulmonary arterial hypertension lung. *Metabolomics*. 2014;10:1169–1175. doi: 10.1007/s11306-014-0653-y.

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension

Christopher J. Rhodes, Pavandeep Ghataorhe, John Wharton, Kevin C. Rue-Albrecht, Charaka Hadinnapola, Geoffrey Watson, Marta Bleda, Matthias Haimel, Gerry Coghlan, Paul A. Corris, Luke S. Howard, David G. Kiely, Andrew J. Peacock, Joanna Pepke-Zaba, Mark R. Toshner, S. John Wort, J. Simon R. Gibbs, Allan Lawrie, Stefan Gräf, Nicholas W. Morrell and Martin R. Wilkins

Circulation. 2017;135:460-475; originally published online November 21, 2016;
doi: 10.1161/CIRCULATIONAHA.116.024602

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circ.ahajournals.org/content/135/5/460>
Free via Open Access

Data Supplement (unedited) at:

<http://circ.ahajournals.org/content/suppl/2016/11/21/CIRCULATIONAHA.116.024602.DC1>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation* is online at:
<http://circ.ahajournals.org/subscriptions/>

SUPPLEMENTAL MATERIAL

Title: Plasma metabolomics implicate modified transfer RNAs and altered bioenergetics in the outcome of pulmonary arterial hypertension

Authors: Christopher J. Rhodes^{1†}, PhD; Pavandeep Ghataorhe^{1†}, BM BCh; John Wharton¹, PhD; Kevin C. Rue-Albrecht¹, PhD; Charaka Hadinnapola², BM BCh; Geoffrey Watson¹, BM BCh; Marta Bleda², PhD; Matthias. Haimel², BSc; Gerry Coghlan³, MD; Paul A. Corris⁴, FRCP; Luke. S. Howard^{5,6}, DPhil; David G. Kiely^{7,8}, MD; Andrew J. Peacock⁹, MD; Joanna Pepke-Zaba¹⁰, PhD; Mark R. Toshner^{2,10}, MD; S. John Wort¹¹, PhD; J. Simon R. Gibbs^{5,6}, MD; Allan Lawrie⁸, PhD; Stefan Gräf^{2,12}, PhD; Nicholas W. Morrell², MD FMedSci; Martin R. Wilkins^{1*‡}, MD FMedSci

Affiliations:

¹Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK

²Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, CB2 0QQ, UK

³Cardiology Department, Royal Free Hospital, London, NW3 2QG, UK

⁴Institute of Cellular Medicine, Newcastle University and The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK

⁵National Pulmonary Hypertension Service, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK

⁶National Heart and Lung Institute (NHLI), Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK

⁷Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK

⁸Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, S10 2RX, UK

⁹Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, G81 4HX, UK

¹⁰Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, CB23 3RE, UK

¹¹Pulmonary Hypertension Service, Royal Brompton Hospital, London, SW3 6NP, UK

¹²Department of Haematology, University of Cambridge, Cambridge, CB2 0PT, UK

*Corresponding author: Dr Martin R Wilkins, MD FMedSci

Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road,
London, W12 0NN, UK.

Email: m.wilkins@imperial.ac.uk,

Tel: 020 3313 2049

†These authors contributed equally to this work

‡On behalf of the NIHR BioResource – Rare Diseases (BRIDGE) PAH Consortium and the
UK National PAH Cohort Study Consortium

Supplementary Materials

Metabolomic profiling methodology

Samples were prepared with use of an automated MicroLab STAR system (Hamilton Company, Reno, NV, USA). For quality control (QC), a pooled sample from all experimental samples was used throughout the experiment, and a mixture of Metabolon QC standards were spiked into all experimental samples to monitor instrument performance and chromatographic alignment. Samples were randomised prior to experimentation.

Experiments were conducted on Waters Acuity ultra-performance liquid chromatography (UPLC) systems (Waters Corporation, Milford, MA, USA) using Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray

ionization (HESI-II) source and Orbitrap mass analyser (Thermo Fisher Scientific, MA, USA).

The analysis platform used four methods for Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy (UPLC-MS/MS) including a) positive ion mode electrospray ionisation (ESI), b) positive ion mode optimised for hydrophobic compounds, c) negative ion mode ESI and d) negative ionisation following elution from a hydrophilic interaction chromatography (HILIC) column. Scan time varied between methods and covered 70-1000m/z.

The resulting spectra were compared to the in-house Metabolon standard library using retention time, mass (m/z), adducts and MS/MS spectra. Analysis using this platform has been applied to measure metabolite levels in human plasma in control ^{1,2} and disease populations ^{3,4}. All experiments and runs were conducted on the same day.

Table S1 (below). Metabolites distinguishing pulmonary arterial hypertension (PAH) from healthy (HC) and disease controls (DC). 97 metabolites that are significantly different between PAH and healthy controls in 3 cohorts ($p < 7.3 \times 10^{-5}$) are shown. Mean values are given and the data is scaled to the healthy control group. Significance from linear regression is shown (p value), and for metabolites with $p > 0.05$ in PAH HC linear regression, the significant confounder is shown. Significance is also shown for Mann Whitney U test between PAH treatment naïve patients versus all HC, and PAH bone morphogenetic protein type 2 receptor (*BMPR2*) mutation carriers versus patients with no *BMPR2* mutation. GPC, glycerophosphocholine. *probable metabolite identity, but unconfirmed (see methods).

Metabolite	Metabolic Pathway	Group averages (z-score relative to healthy control levels)									Statistics (p-values) and major confounders				
		Discovery			Validation1			Validation2	PAH	BMPR2	Linear Regression		Confounder	Sub-analyses	
		HC	DC	PAH (19-70)	HC	DC	PAH	PAH2	Naïve	Mutation	HC vs PAH	HC+DC vs PAH	HC vs PAH	PAH Naïve vs HC	BMPR2 vs PAH
Increased in PAH vs HC and DC (independent of confounders)															
N-acetylaspartate (NAA)	Alanine & Aspartate	0.12	0.21	1.13	-0.11	0.64	1.32	0.87	1.47	0.93	2.3E-04	4.6E-03		3.0E-09	0.46
octadecanedioate	Fatty Acid, Dicarboxylate	0.07	0.12	0.82	-0.07	0.34	0.93	0.35	0.95	0.43	1.5E-02	1.3E-02		7.3E-06	0.25
3-hydroxy-3-methylglutarate	Mevalonate	-0.07	0.57	0.89	0.07	0.57	1.15	0.76	1.20	0.75	3.5E-02	3.0E-02		1.6E-09	0.12
acisoga	Polyamine	-0.10	1.07	1.42	0.09	1.14	1.95	1.22	1.93	1.04	1.9E-04	1.5E-02		2.7E-11	2.9E-02
N1-methylinosine	Purine, Hypo-Xanthine/Inosine	-0.22	0.58	1.50	0.20	0.86	1.85	1.29	1.78	1.50	8.1E-04	2.2E-02		1.5E-13	0.48
xanthine	Purine, Hypo-Xanthine/Inosine	0.11	0.56	0.98	-0.10	0.62	1.06	1.00	1.35	1.16	2.0E-07	2.8E-03		3.4E-09	0.19
N2,N2-dimethylguanosine	Purine, Guanine	-0.11	0.83	1.56	0.10	1.15	2.00	1.39	1.95	1.36	1.1E-02	3.9E-02		2.2E-13	0.11
3-ureidopropionate	Pyrimidine, Uracil	-0.14	0.22	0.62	0.13	0.09	1.16	0.54	1.16	0.47	1.7E-02	9.0E-04		4.0E-09	0.36
malate	TCA Cycle	-0.18	0.60	1.17	0.17	0.69	1.64	1.02	1.81	1.11	8.8E-04	9.1E-03		1.5E-14	0.35
X - 12688	Unknown	-0.11	1.01	1.50	0.10	1.14	1.70	1.26	1.76	0.99	4.9E-05	3.2E-02		6.4E-13	1.6E-02
X - 13737	Unknown	-0.05	0.19	0.97	0.05	0.38	1.03	0.91	1.15	0.94	1.8E-02	6.1E-03		1.9E-08	0.70
X - 21796	Unknown	0.07	0.19	0.96	-0.07	0.44	1.06	0.73	1.33	0.83	5.0E-03	1.3E-02		1.9E-12	0.83
Decreased in PAH vs HC and DC (independent of confounders)															
palmitoylcholine	Fatty Acid (Acyl Choline)	-0.05	-0.14	-1.33	0.05	-0.35	-0.73	-1.10	-0.94	-1.35	1.7E-03	8.3E-03		3.9E-05	4.8E-02
1-arachidonoyl-GPC (20:4n6)*	Lysolipid	-0.08	-0.14	-1.09	0.08	-0.25	-0.74	-0.81	-0.81	-1.00	1.2E-02	3.2E-02		5.9E-05	0.27
1-docosapentaenoyl-GPC (22:5n3)*	Lysolipid	-0.03	-0.17	-1.03	0.03	-0.21	-0.80	-0.84	-0.79	-1.02	9.0E-03	6.7E-03		1.6E-05	0.23
1-linoleoyl-2-eicosapentaenoyl-GPC (18:2/20:5)*	Phospholipid	0.03	-0.39	-0.81	-0.03	-0.13	-1.13	-0.81	-1.16	-0.77	2.4E-02	1.2E-02		3.4E-08	0.68
sphingomyelin (d18:1/20:0, d16:1/22:0)*	Sphingolipid	0.05	-0.43	-1.02	-0.05	-0.38	-1.09	-1.05	-1.24	-0.93	1.3E-02	7.7E-03		1.2E-08	0.49
sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0)*	Sphingolipid	0.03	-0.44	-0.89	-0.03	-0.32	-0.93	-0.76	-1.04	-0.83	2.7E-03	4.0E-02		1.4E-08	0.78
sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)*	Sphingolipid	0.07	-0.37	-1.09	-0.06	-0.32	-1.16	-1.03	-1.21	-1.12	2.6E-03	7.2E-04		1.8E-07	0.95
sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1)*	Sphingolipid	0.04	-0.27	-0.63	-0.04	-0.17	-0.60	-0.54	-0.68	-0.66	4.9E-04	4.4E-02		1.0E-06	0.40

Increased in PAH vs HC (independent of confounders)														
oleoyl ethanolamide	Endocannabinoid	0.10	1.02	0.88	-0.09	1.15	1.02	0.52	0.84	0.29	1.3E-03	2.2E-01	5.6E-05	5.4E-03
3-hydroxybutyrylcarnitine (1)	Fatty Acid (Acyl Carnitine)	0.02	0.52	0.91	-0.01	0.81	0.97	0.60	1.11	0.62	6.1E-05	1.1E-01	7.3E-09	4.5E-02
3-hydroxybutyrylcarnitine (2)	Fatty Acid (Acyl Carnitine)	0.07	0.76	1.26	-0.06	1.02	1.24	0.90	1.49	0.81	4.7E-03	6.8E-01	3.4E-09	3.8E-02
acetylcarnitine	Fatty Acid (Acyl Carnitine)	0.11	0.43	1.02	-0.10	0.77	0.88	0.59	0.94	0.56	1.2E-02	2.9E-01	5.7E-06	3.1E-02
adipoylcarnitine	Fatty Acid (Acyl Carnitine)	-0.04	0.41	1.44	0.04	0.94	1.69	1.25	1.77	1.20	4.6E-02	3.9E-01	5.8E-10	0.09
myristoleoylcarnitine*	Fatty Acid (Acyl Carnitine)	0.04	0.33	0.75	-0.04	0.64	0.85	0.53	0.91	0.37	1.6E-02	4.6E-01	6.2E-05	1.0E-02
myristoylcarnitine	Fatty Acid (Acyl Carnitine)	0.01	0.46	0.81	-0.01	0.87	1.06	0.60	1.07	0.44	4.1E-02	9.5E-01	9.4E-06	1.1E-02
oleoylcarnitine	Fatty Acid (Acyl Carnitine)	0.03	0.53	0.96	-0.03	0.83	1.39	1.20	1.22	0.87	1.8E-02	6.7E-01	3.2E-07	0.10
palmitoleoylcarnitine*	Fatty Acid (Acyl Carnitine)	0.08	0.56	0.91	-0.07	0.90	1.23	0.85	1.14	0.69	8.5E-03	8.9E-01	7.9E-07	4.1E-02
suberoylcarnitine	Fatty Acid (Acyl Carnitine)	0.10	0.55	1.40	-0.09	0.98	1.61	1.23	1.66	1.03	7.1E-03	3.5E-01	1.3E-09	2.9E-02
glutamate	Glutamate	0.16	0.47	1.13	-0.14	0.41	0.98	0.71	1.12	0.83	2.9E-02	1.4E-01	2.7E-07	0.98
methionine sulfone	Met, Cys, SAM & Tau	-0.03	0.49	1.57	0.03	0.98	1.79	1.40	1.56	1.29	3.6E-02	4.9E-01	1.8E-09	0.14
N-acetylmethionine	Met, Cys, SAM & Tau	-0.04	0.48	1.08	0.04	0.63	1.27	0.60	1.30	0.80	3.3E-03	1.6E-01	1.3E-09	0.22
N-acetyltaurine	Met, Cys, SAM & Tau	0.07	0.56	1.02	-0.06	0.71	1.15	0.63	1.15	0.37	1.0E-03	7.1E-02	2.7E-07	9.7E-04
N-formylmethionine	Met, Cys, SAM & Tau	-0.17	0.49	1.08	0.16	0.69	1.53	0.78	1.59	0.85	4.8E-02	3.0E-01	5.8E-10	0.10
5,6-dihydrothymine	Pyrimidine, Thymine	-0.22	0.65	1.33	0.20	0.96	1.37	0.62	1.38	0.71	2.0E-04	6.7E-02	1.2E-08	0.15
alpha-ketoglutarate	TCA Cycle	-0.04	0.45	0.68	0.04	0.71	1.57	1.13	1.61	1.14	2.2E-02	2.4E-01	2.6E-13	1.00
fumarate	TCA Cycle	-0.15	0.30	0.65	0.13	0.45	1.14	0.56	1.23	0.31	2.1E-02	9.8E-02	3.5E-16	0.28
C-glycosyltryptophan	Tryptophan	-0.05	0.55	1.11	0.05	0.84	1.37	0.76	1.30	0.59	4.8E-02	3.9E-01	5.9E-07	4.7E-03
X - 12127	Unknown	0.06	0.63	0.85	-0.06	0.61	1.05	0.67	1.07	0.73	1.6E-02	4.4E-01	1.6E-08	0.53
X - 12472	Unknown	-0.04	0.71	1.03	0.04	0.82	1.05	0.96	1.15	0.93	3.4E-03	8.2E-01	2.5E-07	0.59
X - 12739	Unknown	-0.09	0.87	1.02	0.08	1.11	1.12	0.99	1.18	0.97	2.4E-02	1.8E-01	6.8E-07	0.35
X - 12824	Unknown	-0.02	0.54	0.85	0.02	0.74	1.08	0.79	1.16	0.78	2.0E-02	6.8E-01	9.5E-08	0.44
X - 17327	Unknown	0.03	0.66	0.86	-0.03	0.81	0.97	0.82	1.02	0.78	2.6E-02	7.0E-01	2.4E-06	0.34
X - 21829	Unknown	-0.07	0.44	0.82	0.06	0.65	1.24	0.66	1.41	0.62	2.5E-02	5.6E-01	2.4E-10	0.10
X - 24307	Unknown	0.04	0.68	0.70	-0.04	0.52	1.18	0.97	1.09	0.94	6.9E-05	7.2E-02	1.2E-07	0.88

X - 24513	Unknown	-0.10	0.67	1.05	0.09	0.92	1.44	0.98	1.30	0.77	2.4E-02	4.8E-01		1.4E-07	9.1E-03
X - 24527	Unknown	-0.08	0.86	1.11	0.08	1.17	1.22	1.06	1.22	0.94	3.5E-02	1.9E-01		2.2E-06	0.25
X - 24678	Unknown	0.21	0.74	1.20	-0.19	0.62	1.34	0.70	1.33	0.83	4.9E-03	1.2E-01		3.6E-11	0.42
X - 24766	Unknown	-0.31	0.45	0.82	0.28	0.60	1.07	0.85	0.89	0.92	1.9E-02	3.9E-01		5.1E-07	0.78
Decreased in PAH vs HC (independent of confounders)															
asparagine	Alanine & Aspartate	-0.06	-0.58	-0.88	0.05	-0.55	-1.00	-0.90	-1.22	-0.95	8.7E-04	8.5E-02		2.3E-07	0.64
dehydroisoandrosterone sulfate (DHEA-S)	Steroid	-0.05	-1.17	-1.53	0.04	-0.95	-1.74	-1.77	-1.53	-1.56	2.5E-02	4.1E-01		1.3E-09	0.46
X - 23765	Unknown	0.09	-0.50	-0.72	-0.08	-0.50	-0.90	-0.90	-1.02	-1.08	8.1E-04	2.0E-01		9.7E-07	0.15
Increased in PAH vs HC															
N-acetylalanine	Alanine & Aspartate	-0.11	0.55	0.76	0.10	0.88	1.15	0.66	1.04	0.50	9.9E-01	2.3E-01	Diuretics	3.2E-05	1.6E-02
N-acetylneuraminate	Aminosugar	-0.11	0.50	0.93	0.11	0.63	0.88	0.47	0.76	0.28	7.4E-02	2.4E-01	Age	1.8E-04	1.0E-03
erythronate*	Aminosugar	-0.11	0.45	0.71	0.10	0.68	1.16	0.59	1.10	0.37	7.1E-01	6.5E-01	Bilirubin	5.4E-06	6.0E-03
N-acetylglucosamine/N-acetylgalactosamine	Aminosugar	-0.14	0.50	0.72	0.13	0.89	0.95	0.58	0.62	0.54	1.0E-01	7.3E-01	Gender	1.8E-03	4.4E-02
gulonic acid*	Ascorbate & Aldarate	-0.08	0.49	0.61	0.07	0.57	0.79	0.61	0.81	0.47	8.5E-01	5.3E-01	Age	4.5E-05	2.8E-02
palmitoylcarnitine	Fatty Acid (Acyl Carnitine)	-0.03	0.49	0.91	0.03	1.03	1.28	0.95	1.23	0.90	6.0E-02	9.2E-01	Bilirubin	1.6E-07	0.43
malonylcarnitine	Fatty Acid Synthesis	0.00	0.20	0.56	0.00	0.29	0.94	0.48	0.96	0.57	1.3E-01	3.8E-02	Bilirubin	3.8E-09	0.53
N-acetylserine	Glycine, Serine & Threonine	-0.16	0.63	1.00	0.15	1.04	1.49	0.97	1.38	0.85	5.2E-01	4.0E-01	Bilirubin	6.9E-08	0.05
N-acetylthreonine	Glycine, Serine & Threonine	-0.22	0.31	0.68	0.20	0.64	0.99	0.55	1.10	0.47	6.5E-01	9.7E-01	Bilirubin	4.4E-07	2.0E-02
1-methylimidazoleacetate	Histidine	-0.05	0.52	0.86	0.04	0.50	1.32	0.86	1.02	0.74	6.0E-02	9.5E-02	Age	7.9E-07	0.08
imidazole propionate	Histidine	-0.21	0.44	0.84	0.19	0.71	0.99	0.79	0.98	0.84	1.4E-01	8.1E-01	Bilirubin	1.1E-07	0.54
quinolinate	Nicotinate & Nicotinamide	-0.11	0.46	0.76	0.10	0.68	1.19	0.86	0.95	0.58	6.0E-01	5.0E-01	Bilirubin	1.8E-04	3.8E-02
vanillylmandelate (VMA)	Phenylalanine & Tyrosine	-0.21	0.35	1.00	0.19	0.37	1.52	0.83	1.75	0.96	2.3E-01	1.5E-02	Age	6.3E-12	0.37
4-acetamidobutanoate	Polyamine	-0.10	0.72	1.22	0.09	0.90	1.93	1.26	1.83	1.19	8.6E-01	7.0E-01	Bilirubin	1.0E-11	0.15
N-acetylputrescine	Polyamine	-0.16	0.66	0.84	0.15	0.72	1.32	0.66	0.93	0.53	5.8E-01	6.2E-01	Bilirubin	3.0E-06	3.8E-02
N6-carbamoylthreonyl adenosine	Purine, Adenine	-0.12	0.58	1.04	0.11	0.90	1.49	1.06	1.31	0.92	1.7E-01	4.5E-01	Age	8.4E-09	4.6E-02
N1-methyladenosine	Purine, Adenine	-0.21	0.70	0.94	0.19	0.91	1.26	0.65	1.03	0.46	8.6E-01	1.4E-01	Bilirubin	2.4E-05	4.4E-03
N6-succinyladenosine	Purine, Adenine	-0.06	0.38	0.63	0.05	0.43	0.86	0.50	0.94	0.44	1.5E-01	2.7E-01	Bilirubin	1.2E-09	2.7E-03
N4-acetylcytidine	Pyrimidine, Cytidine	0.07	0.55	1.31	-0.06	0.77	1.50	1.22	1.33	1.19	2.7E-01	6.7E-01	Bilirubin	1.3E-08	0.47
orotidine	Pyrimidine, Orotate	-0.11	0.58	1.07	0.10	0.95	1.27	0.96	1.27	0.83	2.8E-01	5.3E-01	Bilirubin	1.4E-08	0.08
pseudouridine	Pyrimidine, Uracil	-0.08	0.77	1.22	0.08	1.05	1.66	1.17	1.68	0.97	1.5E-01	8.6E-01	Bilirubin	5.2E-11	1.4E-02

kynurenine	Tryptophan	-0.14	0.29	1.00	0.13	0.57	1.37	0.77	1.44	0.68	5.6E-01	3.3E-01	Bilirubin	1.2E-08	0.07
X - 12100	Unknown	-0.13	0.49	1.04	0.12	0.85	1.26	0.88	1.28	0.75	1.3E-01	4.6E-01	Age	9.8E-08	0.06
X - 11564	Unknown	-0.13	0.51	0.94	0.12	0.90	1.48	0.83	1.43	0.73	9.6E-01	8.8E-01	Bilirubin	3.5E-07	0.06
X - 12026	Unknown	-0.16	0.69	1.58	0.14	1.01	2.01	1.36	2.20	1.26	6.9E-01	7.7E-01	Bilirubin	3.8E-12	0.07
X - 12117	Unknown	-0.12	0.66	1.18	0.11	0.98	1.55	1.35	1.50	1.20	6.7E-01	3.6E-01	Bilirubin	7.7E-09	0.19
X - 15503	Unknown	-0.17	0.28	1.04	0.15	0.70	1.64	1.06	1.68	1.33	6.3E-01	5.6E-02	Bilirubin	2.5E-10	0.63
X - 11429	Unknown	-0.07	0.88	1.52	0.07	1.31	1.98	1.45	1.88	1.18	9.1E-02	8.4E-01	Diuretics	3.4E-10	2.0E-02
X - 21736	Unknown	-0.06	0.33	1.04	0.06	0.59	1.46	0.92	1.57	0.95	2.7E-01	3.5E-01	Diuretics	1.1E-10	0.42
pro-hydroxy-pro	Urea cycle; Arginine & Proline	-0.03	0.32	0.87	0.03	0.51	1.24	0.90	1.07	0.98	9.6E-01	6.9E-01	Diuretics	2.9E-06	0.95
Decreased in PAH vs HC															
histidine	Histidine	-0.07	-0.74	-1.57	0.06	-0.91	-1.89	-1.71	-1.78	-1.60	6.1E-02	8.2E-03	Prostanoids	1.2E-11	4.2E-01
1-linoleoyl-GPC (18:2)	Lysolipid	-0.10	-0.59	-1.22	0.09	-0.51	-1.14	-1.12	-1.33	-1.10	5.8E-02	2.4E-02	Bilirubin	1.3E-07	5.2E-01
2-linoleoyl-GPC (18:2)*	Lysolipid	-0.11	-0.55	-1.23	0.10	-0.42	-0.97	-1.09	-1.35	-1.15	9.4E-02	2.9E-02	Bilirubin	4.5E-08	9.6E-01
1-dihomo-linoleoyl-GPC (20:2)*	Lysolipid	0.00	-0.39	-0.95	0.00	-0.49	-0.86	-1.14	-0.98	-1.30	2.4E-01	4.3E-01	Statins	5.5E-05	1.2E-01
1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)*	Plasmalogen	0.01	-0.38	-1.06	-0.01	-0.17	-1.13	-0.98	-1.28	-1.08	2.3E-01	1.5E-01	PDE5 inhib	5.1E-08	9.4E-01
behenoyl sphingomyelin (d18:1/22:0)*	Sphingolipid	0.02	-0.22	-0.75	-0.01	-0.20	-0.71	-0.92	-0.78	-0.77	1.4E-01	3.0E-02	Gender	3.6E-06	8.4E-01
4-androsten-3beta,17beta-diol disulfate (1)	Steroid	-0.04	-0.64	-0.87	0.03	-0.47	-0.81	-1.14	-0.55	-1.06	2.4E-01	5.4E-01	Gender	4.0E-03	6.8E-01
4-androsten-3beta,17beta-diol monosulfate (1)	Steroid	-0.01	-0.85	-1.15	0.01	-0.68	-1.30	-1.40	-1.18	-1.32	5.6E-02	3.7E-01	Gender	5.8E-07	9.3E-01
androsterone sulfate	Steroid	-0.02	-0.70	-1.33	0.02	-0.69	-1.40	-1.40	-1.14	-1.33	1.5E-01	2.0E-01	Gender	4.6E-06	7.3E-01
epiandrosterone sulfate	Steroid	-0.02	-0.86	-1.42	0.01	-0.72	-1.50	-1.49	-1.23	-1.40	1.3E-01	3.9E-01	Gender	1.1E-06	6.4E-01
pregn steroid monosulfate*	Steroid	-0.08	-0.83	-0.88	0.07	-0.68	-0.93	-1.04	-0.71	-0.84	1.0E-01	6.7E-01	Gender	3.3E-04	2.6E-01
X - 23749	Unknown	0.04	-0.16	-1.10	-0.03	-0.34	-1.05	-1.12	-0.94	-1.41	2.0E-01	2.7E-01	BMI	5.4E-05	0.02
arginine	Urea cycle; Arginine & Proline	-0.05	-0.67	-1.05	0.04	-0.79	-1.40	-1.47	-1.80	-1.32	1.1E-01	3.1E-01	DM drugs	2.1E-11	6.5E-01
homoarginine	Urea cycle; Arginine & Proline	-0.05	-0.70	-0.91	0.05	-0.59	-1.13	-1.06	-1.11	-0.86	5.1E-02	2.1E-01	Ethnicity	4.8E-07	7.6E-02

Table S1. Metabolites distinguishing pulmonary arterial hypertension (PAH) from healthy (HC) and disease controls (DC). 97 metabolites that are significantly different between PAH and healthy controls in 3 cohorts ($p < 7.3 \times 10^{-5}$) are shown. Mean values are given and the data is scaled to the healthy control group. Significance from linear regression is shown (p value), and for metabolites with $p > 0.05$ in PAH HC linear regression, the significant confounder is shown. Significance is also shown for Mann Whitney U test between PAH treatment naïve patients versus all HC, and PAH bone morphogenetic protein type 2 receptor (*BMP2*) mutation carriers versus patients with no *BMP2* mutation. GPC, glycerophosphocholine. *probable metabolite identity, but unconfirmed (see methods).

Table S2. (below) Survival analysis.

Metabolite	Metabolic Pathway	Discovery		Validation1	
		Hazard Ratio	Sig	Hazard Ratio	Sig
Higher value indicates mortality. Independent of established prognostic markers					
N-acetylalanine	Alanine and Aspartate	2.02 (1.22-3.36)	6.43E-03	2.08 (1.12-3.86)	2.04E-02
pimeloylcarnitine/3-methyladipoylcarnitine	Fatty Acid (Acyl Carnitine)	2.16 (1.28-3.66)	4.03E-03	2.52 (1.24-5.10)	1.04E-02
1-methylimidazoleacetate	Histidine	2.26 (1.37-3.73)	1.43E-03	1.74 (1.03-2.93)	3.93E-02
N-acetylmethionine	Methionine, Cysteine, SAM and Taurine	2.36 (1.41-3.96)	1.16E-03	2.29 (1.18-4.43)	1.44E-02
N-formylmethionine	Methionine, Cysteine, SAM and Taurine	1.79 (1.20-2.68)	4.50E-03	1.98 (1.20-3.25)	7.15E-03
4-acetamidobutanoate	Polyamine	2.20 (1.45-3.35)	2.19E-04	2.02 (1.30-3.14)	1.83E-03
N-acetylputrescine	Polyamine	1.74 (1.04-2.91)	3.54E-02	2.92 (1.51-5.66)	1.50E-03
N1-methylinosine	Purine , (Hypo)Xanthine/Inosine	2.82 (1.74-4.57)	2.42E-05	1.73 (1.09-2.77)	2.11E-02
urate	Purine , (Hypo)Xanthine/Inosine	1.61 (1.06-2.42)	2.43E-02	2.14 (1.26-3.64)	4.73E-03
N6-succinyladenosine	Purine , Adenine	3.89 (1.40-10.82)	9.18E-03	8.31 (1.94-35.54)	4.29E-03
N6-carbamoylthreonyladenosine	Purine , Adenine	3.10 (1.60-6.00)	8.04E-04	2.08 (1.08-4.00)	2.81E-02
N1-methyladenosine	Purine , Adenine	1.94 (1.25-3.01)	2.92E-03	1.93 (1.12-3.32)	1.75E-02
N2,N2-dimethylguanosine	Purine , Guanine	2.53 (1.57-4.08)	1.35E-04	1.86 (1.14-3.03)	1.25E-02
pseudouridine	Pyrimidine , Uracil	1.78 (1.07-2.94)	2.54E-02	2.75 (1.48-5.12)	1.45E-03
X - 24020	Unknown	2.47 (1.42-4.30)	1.36E-03	1.84 (1.00-3.39)	4.94E-02
X - 24513	Unknown	2.34 (1.28-4.29)	5.92E-03	2.18 (1.11-4.29)	2.34E-02
X - 12472	Unknown	2.24 (1.44-3.47)	3.11E-04	1.57 (1.00-2.46)	4.97E-02
X - 12739	Unknown	2.07 (1.41-3.04)	2.07E-04	1.56 (1.06-2.28)	2.28E-02
X - 24527	Unknown	1.85 (1.38-2.48)	4.09E-05	1.43 (1.03-1.99)	3.12E-02
X - 12688	Unknown	1.81 (1.23-2.68)	2.83E-03	2.02 (1.27-3.19)	2.80E-03
X - 24728	Unknown	1.70 (1.09-2.64)	1.96E-02	2.04 (1.09-3.79)	2.50E-02
X - 15503	Unknown	1.67 (1.11-2.52)	1.38E-02	1.51 (1.03-2.22)	3.48E-02
X - 11564	Unknown	1.62 (1.10-2.38)	1.49E-02	1.60 (1.03-2.47)	3.51E-02

X - 24411	Unknown	1.54 (1.04-2.27)	3.05E-02	2.16 (1.32-3.54)	2.17E-03
X - 11429	Unknown	1.47 (1.05-2.06)	2.65E-02	1.79 (1.18-2.71)	5.76E-03
Lower value indicates mortality. Independent of established prognostic markers					
1-eicosapentaenoyl-GPE (20:5)*	Lysolipid	0.60 (0.43-0.84)	2.65E-03	0.62 (0.39-1.00)	4.98E-02
1-eicosapentaenoyl-GPC (20:5)*	Lysolipid	0.47 (0.31-0.73)	6.30E-04	0.50 (0.31-0.82)	6.05E-03
1-linoleoyl-2-docosaheptaenoyl-GPC (18:2/22:6)*	Phospholipid	0.64 (0.46-0.89)	7.40E-03	0.65 (0.47-0.91)	1.27E-02
1-oleoyl-2-docosaheptaenoyl-GPC (18:1/22:5n6)*	Phospholipid	0.64 (0.47-0.87)	4.11E-03	0.62 (0.43-0.90)	1.06E-02
1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)*	Phospholipid	0.57 (0.39-0.83)	3.68E-03	0.68 (0.48-0.96)	2.66E-02
phosphatidylcholine (18:0/20:5, 16:0/22:5n6)*	Phospholipid	0.54 (0.37-0.77)	7.30E-04	0.42 (0.25-0.72)	1.44E-03
1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5)*	Phospholipid	0.53 (0.37-0.75)	4.11E-04	0.43 (0.26-0.74)	1.96E-03
1-linoleoyl-2-eicosapentaenoyl-GPC (18:2/20:5)*	Phospholipid	0.48 (0.33-0.70)	1.38E-04	0.60 (0.41-0.88)	8.59E-03
1-myristoyl-2-docosaheptaenoyl-GPC (14:0/22:6)*	Phospholipid	0.47 (0.31-0.72)	4.84E-04	0.49 (0.29-0.81)	5.62E-03
dehydroisoandrosterone sulfate (DHEA-S)	Steroid	0.71 (0.52-0.97)	3.19E-02	0.55 (0.33-0.91)	2.06E-02
X - 24041	Unknown	0.46 (0.29-0.72)	6.88E-04	0.61 (0.38-0.99)	4.45E-02
Higher value indicates mortality					
hexadecanedioate	Fatty Acid, Dicarboxylate	1.53 (1.09-2.14)	1.40E-02	1.67 (1.16-2.41)	5.58E-03
N-acetyltaurine	Methionine, Cysteine, SAM and Taurine	1.97 (1.16-3.35)	1.19E-02	2.24 (1.13-4.43)	2.05E-02
3-hydroxy-3-methylglutarate	Mevalonate	1.68 (1.03-2.74)	3.78E-02	2.08 (1.02-4.23)	4.40E-02
vanillylmandelate (VMA)	Phenylalanine and Tyrosine	1.48 (1.06-2.06)	2.02E-02	1.58 (1.06-2.34)	2.38E-02
N-acetyl-beta-alanine	Pyrimidine , Uracil	1.54 (1.08-2.21)	1.80E-02	1.65 (1.18-2.32)	3.65E-03
fumarate	TCA Cycle	1.70 (1.00-2.88)	4.97E-02	2.57 (1.09-6.06)	3.09E-02
N2,N5-diacetylornithine	Urea cycle; Arginine and Proline	2.15 (1.27-3.63)	4.37E-03	2.15 (1.13-4.09)	1.95E-02
Lower value indicates mortality					
valine	Leucine, Isoleucine and Valine	0.66 (0.49-0.89)	6.80E-03	0.68 (0.48-0.95)	2.21E-02
1-docosaheptaenoyl-GPE (22:6)*	Lysolipid	0.68 (0.49-0.94)	1.86E-02	0.54 (0.34-0.85)	8.27E-03
1-dihomo-linolenoyl-GPC (20:3n3 or 6)*	Lysolipid	0.57 (0.41-0.79)	7.43E-04	0.71 (0.53-0.96)	2.82E-02
1-docosaheptaenoyl-GPC (22:6)*	Lysolipid	0.54 (0.35-0.81)	3.17E-03	0.57 (0.35-0.93)	2.32E-02
phosphatidylcholine (16:0/22:5n3, 18:1/20:4)*	Phospholipid	0.68 (0.48-0.96)	2.64E-02	0.59 (0.36-0.98)	4.16E-02
1-stearoyl-2-docosaheptaenoyl-GPE (18:0/22:6)*	Phospholipid	0.64 (0.47-0.88)	5.99E-03	0.52 (0.32-0.85)	8.73E-03
1-palmitoleoyl-2-docosaheptaenoyl-GPC (16:1/22:6)*	Phospholipid	0.62 (0.43-0.90)	1.09E-02	0.50 (0.28-0.88)	1.67E-02

1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6)*	Phospholipid	0.62 (0.42-0.90)	1.30E-02	0.34 (0.17-0.68)	1.96E-03
1-stearoyl-2-docosahexaenoyl-GPC (18:0/22:6)	Phospholipid	0.60 (0.42-0.87)	7.16E-03	0.45 (0.27-0.76)	2.76E-03
1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3)*	Phospholipid	0.58 (0.41-0.82)	2.11E-03	0.50 (0.30-0.83)	8.18E-03
1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6)*	Phospholipid	0.58 (0.38-0.88)	9.67E-03	0.54 (0.35-0.84)	6.47E-03
1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPC (P-18:0/22:6)*	Plasmalogen	0.56 (0.37-0.85)	6.20E-03	0.57 (0.33-0.98)	4.06E-02
1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPE (P-18:0/22:6)*	Plasmalogen	0.55 (0.37-0.82)	3.45E-03	0.49 (0.27-0.91)	2.31E-02
1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (P-16:0/22:6)*	Plasmalogen	0.54 (0.37-0.79)	1.31E-03	0.53 (0.32-0.87)	1.30E-02
1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPE (P-16:0/22:6)*	Plasmalogen	0.49 (0.34-0.71)	1.63E-04	0.47 (0.26-0.82)	8.30E-03
sphingomyelin (d18:2/14:0, d18:1/14:1)*	Sphingolipid	0.73 (0.53-1.00)	4.83E-02	0.48 (0.30-0.77)	2.36E-03
sphingomyelin (d18:1/20:0, d16:1/22:0)*	Sphingolipid	0.60 (0.41-0.87)	6.60E-03	0.57 (0.35-0.93)	2.32E-02
sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)*	Sphingolipid	0.59 (0.42-0.83)	2.51E-03	0.53 (0.33-0.85)	7.63E-03
behenoyl sphingomyelin (d18:1/22:0)*	Sphingolipid	0.42 (0.27-0.64)	5.94E-05	0.47 (0.27-0.82)	7.42E-03

Table S2. Survival analysis in PAH. 62 metabolites significantly different between PAH survivors and non-survivors in discovery and validation1 cohorts (p<0.05) are shown. Hazard ratio and significance (Sig) is shown from Cox regression analysis. Hazard ratios shown are for 1 standard deviation change in each metabolite for ease of comparison. Metabolites which are also independent of established prognostic markers in the discovery cohort are also shown.

*probable metabolite identity, but unconfirmed (see methods). GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine.

Pathway	Result	Metabolite	HC v PAH	Prognosis
Fatty Acid Metabolism(Acyl Carnitine)	4.5E-05	3-hydroxybutyrylcarnitine (1)	6E-05	0.3499
		pimeloylcarnitine/3-methyladipoylcarnitine	NA	0.0006
		suberoylcarnitine	0.0071	0.0044
		3-hydroxybutyrylcarnitine (2)	0.0047	0.0046
		palmitoleoylcarnitine*	0.0085	0.3042
		adipoylcarnitine	0.0464	0.0106
		acetylcarnitine	0.0118	0.141
		myristoleoylcarnitine*	0.0165	0.6142
		oleoylcarnitine	0.0176	0.0598
		myristoylcarnitine	0.0412	0.2631
		palmitoylcarnitine	0.0604	0.1959
		linoleoylcarnitine*	NA	0.0615
		hexanoylcarnitine	NA	0.5981
		stearoylcarnitine	NA	0.6611
		octanoylcarnitine	NA	0.8074
		laurylcarnitine	NA	0.8641
		decanoylcarnitine	NA	0.912
		cis-4-decenoyl carnitine	NA	0.9541
Polyamine Metabolism	0.01079	N-acetylputrescine	0.5825	2E-05
		4-acetamidobutanoate	0.8618	3E-05
		acisoga	0.0002	0.0003
Alanine and Aspartate Metabolism	0.02412	5-methylthioadenosine (MTA)	NA	0.0433
		N-acetylaspartate (NAA)	0.0002	0.2634
		asparagine	0.0009	0.9422
		N-acetylalanine	0.9901	0.009
		alanine	NA	0.6529
Purine Metabolism, (Hypo)Xanthine/Inosine containing	0.04317	aspartate	NA	0.9677
		xanthine	2E-07	0.438
		urate	NA	0.0004
		N1-methylinosine	0.0008	0.0144
		AICA ribonucleotide	NA	0.0066
Purine Metabolism, Adenine containing	0.04317	allantoin	NA	0.0934
		hypoxanthine	NA	0.6652
		N6-carbamoylthreonyladenosine	0.1735	7E-05
		N6-succinyladenosine	0.1452	0.0005
		N1-methyladenosine	0.8632	0.0006
		adenine	NA	0.4835
		adenosine	NA	0.5677
Pyrimidine Metabolism, Uracil containing	0.04317	adenosine 5'-monophosphate (AMP)	NA	0.5988
		pseudouridine	0.1506	6E-05
		N-acetyl-beta-alanine	NA	0.0002
		3-ureidopropionate	0.0175	0.0024
		uridine	NA	0.2684
		5-methyluridine (ribothymidine)	NA	0.5196
		beta-alanine	NA	0.8665

Table S3. Pathway enrichment analysis results. Pathways analysed and enrichment p-values are given, as well as metabolites within each pathway and significance values from tests used to select metabolites considered to be disease-associated. HC v PAH, significance of PAH on metabolite levels after controlling for potential confounders by linear regression; Prognosis, weakest significance of metabolite association with survival by Cox analysis in discovery or validation cohorts. *probable metabolite identity, but unconfirmed (see methods).

Metabolite	Area	Sig.	95% CI
3-hydroxy-3-methylglutarate	0.75	2.05E-04	0.63 - 0.86
3-hydroxybutyrylcarnitine (2)	0.67	1.10E-02	0.54 - 0.79
4-acetamidobutanoate	0.67	8.40E-03	0.56 - 0.79
5,6-dihydrothymine	0.67	1.04E-02	0.55 - 0.79
acetylcarnitine	0.65	2.80E-02	0.52 - 0.77
C-glycosyltryptophan	0.66	1.82E-02	0.53 - 0.78
fumarate	0.67	1.01E-02	0.55 - 0.79
hexadecanedioate	0.65	2.32E-02	0.52 - 0.78
malate	0.69	3.32E-03	0.58 - 0.81
N1-methyladenosine	0.69	3.62E-03	0.57 - 0.81
N2,N2-dimethylguanosine	0.69	4.70E-03	0.57 - 0.80
N-acetylalanine	0.67	1.01E-02	0.55 - 0.79
N-acetylmethionine	0.76	6.94E-05	0.66 - 0.87
N-acetylputrescine	0.69	4.07E-03	0.57 - 0.81
N-acetyltaurine	0.68	6.40E-03	0.56 - 0.80
N-formylmethionine	0.67	8.63E-03	0.56 - 0.79
X - 11564	0.65	2.16E-02	0.53 - 0.77
X - 12127	0.65	2.43E-02	0.53 - 0.77
X - 12472	0.65	2.32E-02	0.53 - 0.77
X - 12688	0.68	5.26E-03	0.57 - 0.80
X - 12739	0.68	7.75E-03	0.56 - 0.79
X - 13737	0.66	1.45E-02	0.54 - 0.78
X - 15503	0.68	5.89E-03	0.56 - 0.80
X - 21796	0.70	3.03E-03	0.59 - 0.80
X - 24020	0.67	1.15E-02	0.55 - 0.78
X - 24527	0.67	8.63E-03	0.55 - 0.79
X - 24766	0.67	1.07E-02	0.55 - 0.78

Table S4. ROC analysis of serial metabolite measurements. Area under the curve values for the association between metabolite level changes (i.e. sample 1 subtracted from sample 2) and survival during follow-up are shown for significantly associated metabolites. *probable metabolite identity, but unconfirmed (see methods).

	Controls n=30	PAH (19-70) n=69	PAH (>70) n=8
Female:Male ratio	2.0	2.3	3.0
Age	48.5 +/- 13.1	48.3 +/- 14.1	75.6 +/- 8.1
Angiogenin conc., ng/ml	360 +/- 110.3	479.7 +/- 176.6	554.9 +/- 234.2
N2,N2-dimethylguanosine	-0.1 +/- 1	1.6 +/- 1.2	2.7 +/- 1.4

Table S5. Demographics and circulating factor levels in subjects used for angiogenin study.

Mean +/- standard deviation is shown for continuous variables.




Fig. S1. Metabolite levels in BMRP2 mutation carriers. (A) Average metabolite levels in PAH BMRP2 mutation carriers, non-carriers and control subjects for 20 metabolites found to significantly distinguish PAH and both healthy and disease controls, independent of potential confounders. **(B)** Correlation of average metabolite levels in BMRP2 mutation carriers and non-carriers relative to controls for 53 metabolites that distinguish PAH from healthy controls, independent of potential

confounders. Values plotted are z-scores calculated based on mean and standard deviation of all healthy volunteers in study - negative values indicate metabolites at lower levels in patients versus healthy controls and positive values indicate higher levels of metabolites in patients. *probable metabolite identity, but unconfirmed (see methods).




Fig. S2– Survival analysis of PAH patients. (A) Receiver operating characteristic (ROC) curve for N2,N2-dimethylguanosine in the discovery cohort at 3 years of follow-up. The optimal cut-off for high/low risk levels of N2,N2-dimethylguanosine was derived from this for **B&C**. Kaplan Meier survival estimates in PAH patients in the discovery (**B**) and first validation (**C**) cohorts.




Fig. S3. Dehydroisoandrosterone-sulphate (DHEA-S). Plasma DHEA-S levels in the discovery cohort are shown for healthy controls (HC) and PAH (19-70) with (A) separation by gender and (B) against age.

Supplementary References

1. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, Arnold M, Erte I, Forgetta V, Yang TP, Walter K, Menni C, Chen L, Vasquez L, Valdes AM, Hyde CL, Wang V, Ziemek D, Roberts P, Xi L, Grundberg E, Multiple Tissue Human Expression Resource C, Waldenberger M, Richards JB, Mohny RP, Milburn MV, John SL, Trimmer J, Theis FJ, Overington JP, Suhre K, Brosnan MJ, Gieger C, Kastenmuller G, Spector TD and Soranzo N. An atlas of genetic influences on human blood metabolites. *Nature genetics*. 2014;46:543-50.
2. Guo L, Milburn MV, Ryals JA, Lonergan SC, Mitchell MW, Wulff JE, Alexander DC, Evans AM, Bridgewater B, Miller L, Gonzalez-Garay ML and Caskey CT. Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. *Proceedings of the National Academy of Sciences of the United States of America*. 2015;112:E4901-10.
3. Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, Jaffa M, Milburn MV, Ryals JA, Bowser R, Cudkovic ME, Berry JD and Northeast ALSC. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2014;15:362-70.
4. Miller MJ, Kennedy AD, Eckhart AD, Burrage LC, Wulff JE, Miller LA, Milburn MV, Ryals JA, Beaudet AL, Sun Q, Sutton VR and Elsea SH. Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism. *Journal of Inherited Metabolic Disease*. 2015;38:1029-39.